

Maternal Exposures Data Collection

Presenters: Lisa Chyi, Angela Huang, Bob Castro, Beate Danielsen,
Henry Lee

June 24, 2019 1-2PM

Agenda

Time	Topic	Presenter
1:00 PM	Maternal Exposures Overview	Lisa Chyi
1:15 PM	Case Study	Bob Castro
1:30 PM	Case Study	Angela Huang
1:45 PM	Mother & Baby Substance Exposure Initiative	Henry C. Lee
1:55 PM	Questions	Group
2:00 PM	Adjourn	Group

Maternal Exposures Data Collection Overview

Purpose

- The purpose of this data collection is to improve healthcare for newborns exposed by focusing on treatment and length of stay in the hospital. Using the CPQCC database and partnering with the community of neonatologists and pediatricians committed to improving the quality of care in California, we have a unique opportunity to collect data about the variations in practice and important associates with the outcome of infants that have been exposed in-utero.

Maternal Exposures Data Collection Overview

Eligibility


- Any infant greater than or equal to 34 weeks gestation with an **in-utero** history of exposure to opioids/narcotics (prescribed or illicit) with Neonatal Abstinence Syndrome (NAS) withdrawal symptoms by Day of Life 7. See list of drugs for complete eligibility:
 - Buprenorphine (Subutex, Suboxone)
 - Codeine
 - Fentanyl
 - Heroin
 - Hydrocodone
 - Hydromorphone
 - Methadone
 - Oxycodone
 - Other

Reference:

Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn. American Academy of Pediatrics Clinical Report. Neonatal drug withdrawal. Pediatrics. 2012;129(2). Available at: www.pediatrics.org/cgi/content/full/129/2/e540

Maternal Exposures Data Collection Overview

Advancing NAS Management



Mother & Baby Substance Exposure Initiative

A joint QI project with CMQCC and Health Management Associates

CPQCC is also working jointly with our sister organization, CMQCC, and with Health Management Associates to improve the outcomes for mothers and their newborns affected by opioids



Maternal Exposures Data Collection vs. Mother & Baby Substance Exposure Initiative

Program	What Is It?	Key Components	Who Can Join?	Sponsor
The Mother & Baby Substance Exposure Initiative “Opioid Collaborative”	Quality Improvement Collaborative aimed at: *Emphasizing care that maintains the mother-baby dyad *Addressing treatment of substance use/exposure (with a focus on opioids) for both mother and newborn	*Toolkit of best practices to improve mother and newborn care *Work with Mentor team to support QI implementation *Reports to track progress (Data can be submitted through either the CMQCC Maternal Data Center or the CPQCC Mat Ex Database)	California hospitals in select counties	Jointly-led by CMQCC, CPQCC and HMA
Maternal Exposure Data Collection Pilot “Mat Ex Database”	Data collection project aimed at informing treatment for at-risk infants	*Comprehensive data collection platform *Reports to help hospitals identify areas of high and low performance *Data designed to inform research	Any California hospital with a perinatal service line	CPQCC

Maternal Exposures Data Collection vs. Mother & Baby Substance Exposure Initiative

Options for participation

- Participate in the Maternal Exposures Data Collection only
- Participate in the Mother & Baby Substance Exposure Initiative only
- Participate in both the Maternal Exposures Data Collection and in the Mother & Baby Substance Exposure Initiative

Mother & Baby Substance Exposure Initiative

Select counties throughout California

Identified counties throughout California to participate in a 12-month hospital quality improvement collaborative

Humboldt

Lake

Mendocino

Shasta

Stanislaus

Orange

Ventura

San Diego

San Joaquin

Mother & Baby Substance Exposure Initiative

Hospital Quality Improvement Collaborative

Goals:

- Work with hospitals in the identified counties around perinatal substance exposure, with an emphasis on opioids
- Improve the care and outcomes for both mothers and their newborns
- Maintain the mother-baby dyad
- Help make connections prenatally and after discharge, so mother and baby access wraparound services and continued support

Mother & Baby Substance Exposure Initiative

QI Collaborative

During the 12-month Quality Improvement Collaborative:

- Access to the toolkit and implementation guide
- Support with implementation from a mentor team consisting of an expert in maternal care and an expert in newborn care
- Sharing of learnings with other collaborative-participating hospitals
- Access to Technical Assistance
- Near real-time data in the CMQCC Maternal Data Center to work on Quality Improvement
- Participation is free

Mother & Baby Substance Exposure Initiative: Collaborative Measures

Outcome Measures

Average length of stay for newborns with Neonatal Abstinence Syndrome (NAS)

Structure Measures

Has your hospital implemented a universal screening protocol for OUD?

Has your hospital implemented post-delivery and discharge pain management prescribing practices for routine vaginal and cesarean birth focused on limiting opioid prescriptions?

Has your hospital implemented specific pain management and opioid prescribing guidelines for OUD patients?

Mother & Baby Substance Exposure Initiative: Collaborative Measures

Process Measures

Percent of affiliated prenatal care sites which have implemented a universal screening protocol for OUD

Percent of women with OUD during pregnancy who receive MAT or behavioral health treatment

Percent of women with OUD meeting all maternal safe discharge checklist criteria

Percent of Opioid Exposed Newborns (OEN) rooming in with mother at any time during stay

Percent of OEN receiving any mother's milk at newborn discharge

Percent of OEN who go home to biological mother

Mother & Baby Substance Exposure Initiative

QI Collaborative Kickoff Meeting

Save the date

Quality improvement collaborative kickoff meeting will take place on two dates at the end of September

If your hospital is located within one of the selected counties, we may reach out to your hospital with more details in the coming weeks

If interested in participating or for more information, please contact **Christina Oldini**
Clinical Lead (cmoldini@stanford.edu) or find more information at www.cmqcc.org

For more information on the Mother & Baby Substance Exposure Initiative, visit our websites:

<https://www.cpqcc.org/improvement/projects/substance-exposure-utero>

<https://www.cmqcc.org/qi-initiatives/mother-baby-substance-exposure-initiative>

Questions?

Interested in participating the CPQCC Maternal Exposures Database?

Please submit a Help Ticket at www.cpqcchelp.org to request access.

CPQC